Development of Machine Learning tools for in silicon chimeric antigen receptor (CAR) design

开发用于硅嵌合抗原受体（CAR）设计的机器学习工具

• 批准号: 10026469
• 金额: $ 50.83万
• 依托单位: CODING BIO LIMITED
• 依托单位国家: 英国
• 项目类别: Collaborative R&D
• 财政年份: 2022
• 资助国家: 英国
• 起止时间: 2022 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=10026469
• 关键词: Development; Machine; Learning; tools; silicon

Adoptive cell therapy is a treatment of patients using their own, modified immune cells. It involves harvesting T cells - the immune cells that normally recognise and eliminate pathogens - from the patient's blood, reprogramming them to recognise cancer cells and re-introducing the newly modified cells back into the patient to destroy tumours. The modifying factor used to arm these T cells against cancer is called Chimeric Antigen Receptor or CAR, in short. Using the lock and key analogy, just as every lock can only be opened with the appropriate key, each type of cancer, with its unique antigens, can only be recognised by a specific engineered CAR.Currently, the National Health Service (NHS) is providing CAR-T cell therapy against malignant B cells that express antigen called CD19 to children and young adults with relapsed or difficult-to-treat leukaemia and lymphoma. The treatment is particularly effective in patients who did not respond to chemotherapy, offering real hope to those who otherwise would have no other options. However, this CAR therapy can only treat a very specific type of cancer, leaving much room for improvement. The concerted efforts into the development of specific CAR therapies against other cancers are hindered by the tedious process of target discovery and receptor optimisation.Coding.bio is streamlining the process of building better receptors, making it faster, cheaper, and more diverse. Our objective is to help bring this transformative therapy to a wider patient population.

免疫细胞疗法是一种使用患者自身的修饰免疫细胞的治疗方法。它涉及从患者血液中收获T细胞-通常识别和消除病原体的免疫细胞，重新编程它们以识别癌细胞，并将新修饰的细胞重新引入患者体内以摧毁肿瘤。用于武装这些T细胞对抗癌症的修饰因子被称为嵌合抗原受体或CAR。使用锁和钥匙的类比，就像每把锁只能用合适的钥匙打开一样，每种类型的癌症都有其独特的抗原，只能被特定的工程CAR识别。目前，英国国民健康服务（NHS）正在为患有复发或难以治疗的白血病和淋巴瘤的儿童和年轻人提供针对表达CD 19抗原的恶性B细胞的CAR-T细胞疗法。这种治疗方法对化疗无效的患者特别有效，为那些没有其他选择的患者提供了真实的希望。然而，这种CAR疗法只能治疗一种非常特定类型的癌症，还有很大的改进空间。开发针对其他癌症的特异性CAR疗法的共同努力受到靶点发现和受体的繁琐过程的阻碍，optimisation.Coding.bio正在简化构建更好受体的过程，使其更快，更便宜，更多样化。我们的目标是帮助将这种变革性疗法带给更广泛的患者群体。